Post-earnings recap
Reported
Thu, Mar 3, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Tyra Biosciences reported a loss that was worse than expected, leading to a significant drop in their stock price by over 10%. The lack of revenue information and guidance contributed to investor uncertainty. Overall, the market reacted negatively as the company did not provide clear direction for the future.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.24 | N/A | -14.29% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach moving forward. They highlighted the importance of their current projects but did not offer specific future expectations.
Management did not provide specific guidance for the upcoming quarters.
The company is focused on its ongoing projects and development pipeline.